MSA Knowledge Gaps — Alpha-Synucleinopathy Research Priorities

Last Updated: 2026-03-31 PT

Introduction

Multiple System Atrophy (MSA) is a rare, rapidly progressive neurodegenerative disorder classified as an alpha-synucleinopathy. Despite being part of the same pathological family as [Parkinson's Disease](/diseases/parkinsons-disease) and [Dementia with Lewy Bodies](/diseases/dementia-lewy-bodies), MSA has received significantly less research attention and funding. This gap analysis identifies the critical knowledge gaps that, if addressed, could accelerate therapeutic development for this devastating disease.

Last Updated: 2026-03-31 PT

Introduction

Multiple System Atrophy (MSA) is a rare, rapidly progressive neurodegenerative disorder classified as an alpha-synucleinopathy. Despite being part of the same pathological family as [Parkinson's Disease](/diseases/parkinsons-disease) and [Dementia with Lewy Bodies](/diseases/dementia-lewy-bodies), MSA has received significantly less research attention and funding. This gap analysis identifies the critical knowledge gaps that, if addressed, could accelerate therapeutic development for this devastating disease.

This analysis compares MSA-specific gaps against the broader alpha-synucleinopathy landscape, drawing on the more extensively characterized PD and DLB research priorities documented in [Parkinson's Disease Knowledge Gaps](/gaps/parkinsons) and [Dementia with Lewy Bodies Knowledge Gaps](/gaps/dementia-lewy-bodies).

2025-2026 Research Updates

Diagnostic Advances (2025-2026)

• Alpha-synuclein RT-QuIC: Improved sensitivity for MSA detection in CSF and skin biopsy specimens[@fujimoto2025]
• MRI consensus criteria: Updated 2025 MRI criteria for MSA subtypes showing improved diagnostic accuracy[@valencia2025]
• Subtype differentiation: Better differentiation between MSA-P and MSA-C using quantitative MRI

Biomarker Developments (2025-2026)

• NfL validation: Longitudinal studies confirm NfL as robust progression marker in MSA[@krismer2025]
• Co-pathology recognition: Growing understanding of alpha-synuclein and tau co-pathology in MSA[@sho2025]
• Neurofilament light chain: Now standard biomarker in MSA clinical trials

Therapeutic Landscape (2025-2026)

• Disease modification trials: Multiple Phase 2 trials testing neuroprotective agents
• α-synuclein targeting: Antibodies and ASO approaches in development
• Symptomatic management: Improved protocols for autonomic dysfunction and movement symptoms

Comparison: MSA vs PD vs DLB Knowledge Landscape

| Dimension | Parkinson's Disease | Dementia with Lewy Bodies | Multiple System Atrophy |
|-----------|-------------------|-------------------------|------------------------|
| Prevalence | ~10 million worldwide | ~1.1 million | ~1.9-4.9 per 100K |
| Research investment | High | Moderate | Very low |
| Disease-modifying trials | Active (GLP-1, LRRK2) | Limited | Essentially none |
| Genetic risk factors | Well-characterized | Emerging | Partially characterized |
| Biomarker infrastructure | PPMI, extensive SAA data | Limited | Minimal |
| Animal models | Multiple validated models | Partial | Poorly developed |
| Knowledge gap documentation | Extensive | Growing | Almost absent |

Key Insight: The MSA Disadvantage

The relative scarcity of MSA research creates a compound disadvantage:

Scoring Methodology

Knowledge gaps are ranked using a multi-dimensional scoring system adapted from other gap analyses in the wiki:

• Impact (1-10): Potential to transform patient outcomes if gap is closed
• Tractability (1-10): Feasibility of addressing through research (availability of tools, models, approaches)
• Under-exploration (1-10): Degree to which the gap has been neglected relative to its importance
• Data availability (1-10): Existing data infrastructure that could support research

Gaps are categorized as:

• Tier 1 (Critical): Total ≥30
• Tier 2 (High Priority): Total 25-29
• Tier 3 (Moderate): Total 20-24

Ranked Knowledge Gaps

Tier 1: Critical Gaps (Score ≥30)

| Rank | Knowledge Gap | Impact | Tractability | Under-exploration | Data | Total | Why It Matters |
|------|---------------|--------|---------------|-------------------|------|-------|----------------|
| 1 | What determines the oligodendrocyte-specific vulnerability to α-synuclein aggregation in MSA (vs neuronal vulnerability in PD/DLB)? | 10 | 8 | 10 | 7 | 35 | This is the fundamental biological question distinguishing MSA. Understanding this could reveal novel therapeutic targets. |
| 2 | Can we develop validated diagnostic biomarkers for MSA to distinguish it from PD and PSP? | 10 | 7 | 10 | 6 | 33 | Misdiagnosis rates of 30%+ in early stages confound all research. |
| 3 | What is the natural history of MSA subtypes (MSA-P vs MSA-C) and what determines phenotype? | 9 | 8 | 9 | 7 | 33 | Better phenotyping would enable subtype-specific clinical trials. |
| 4 | Why does MSA progress so much faster than PD (6-10 years vs 15-20 years median survival)? | 10 | 6 | 9 | 6 | 31 | Rapid progression limits therapeutic window. Understanding mechanisms could reveal intervention points. |
| 5 | What are the optimal outcome measures for MSA clinical trials? | 9 | 7 | 9 | 6 | 31 | No validated disease progression biomarkers. Trials use PD measures that may not capture MSA-specific decline. |

Tier 2: High-Priority Gaps (Score 25-29)

| Rank | Knowledge Gap | Impact | Tractability | Under-exploration | Data | Total | Why It Matters |
|------|---------------|--------|---------------|-------------------|------|-------|----------------|
| 6 | What is the role of glial cytoplasmic inclusions (GCIs) in oligodendrocyte dysfunction—are they toxic or protective? | 8 | 7 | 9 | 6 | 30 | GCIs are the pathological hallmark but their functional role is unclear. |
| 7 | Can we develop animal models that faithfully recapitulate MSA pathology? | 9 | 6 | 9 | 5 | 29 | Poor model availability is a major barrier to therapeutic development. |
| 8 | What is the relationship between autonomic failure timing and disease progression in MSA? | 8 | 7 | 8 | 6 | 29 | Autonomic dysfunction is a defining feature but its relationship to motor progression is poorly understood. |
| 9 | Do GBA and other genetic variants modify MSA phenotype similarly to PD, or differently? | 8 | 7 | 8 | 6 | 29 | Genetic understanding could inform patient stratification. |
| 10 | What drives the poor levodopa response in MSA-P vs good response in PD? | 8 | 7 | 8 | 6 | 29 | Understanding this could reveal mechanisms of dopaminergic degeneration. |
| 11 | Can neurofilament light chain (NfL) be used for prognostic stratification in MSA? | 8 | 8 | 7 | 7 | 30 | NfL is elevated but predictive utility is unclear. |
| 12 | What is the role of myelin dysfunction in MSA pathogenesis—primary or secondary? | 7 | 7 | 8 | 6 | 28 | Myelin loss is prominent but its contribution to disease is unknown. |

Tier 3: Moderate Priority Gaps (Score 20-24)

| Rank | Knowledge Gap | Impact | Tractability | Under-exploration | Data | Total | Why It Matters |
|------|---------------|--------|---------------|-------------------|------|-------|----------------|
| 13 | How does α-synuclein strain differ between MSA, PD, and DLB? | 7 | 6 | 8 | 6 | 27 | Strain differences may explain different clinical presentations. |
| 14 | What is the relationship between REM sleep behavior disorder (RBD) and MSA—prodromal marker or parallel process? | 7 | 7 | 7 | 6 | 27 | RBD is common but its diagnostic utility in MSA is unclear. |
| 15 | Can we identify MSA-specific alpha-synuclein seed amplification assay patterns? | 7 | 6 | 8 | 5 | 26 | SAA is validated for PD but not MSA. |

Cross-Disease Comparisons

MSA vs PD: Shared and Distinct Mechanisms

The relationship between MSA and PD represents a critical knowledge gap. Both are α-synucleinopathies, but with fundamentally different cellular targets:

Shared mechanisms:

• α-Synuclein misfolding and aggregation
• Propagation mechanisms (prion-like spread)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• Mitochondrial dysfunction

• Primary oligodendrocyte pathology (vs neuronal)
• Glial cytoplasmic inclusion formation
• Earlier and more severe autonomic failure
• Myelin degeneration
• More rapid progression

MSA vs DLB: Differential Diagnosis

DLB shares with MSA the feature of autonomic dysfunction, but the timing and severity differ:

• DLB: Autonomic dysfunction typically occurs after cognitive symptoms
• MSA: Autonomic failure is often the presenting symptom

Research Priorities Summary

Top 5 Priority Research Questions

Strategic Recommendations

Based on the gap analysis, the following research directions would have highest impact:

Cross-References

• [Multiple System Atrophy](/diseases/multiple-system-atrophy) — Main disease page
• [MSA Genetic Variants](/diseases/msa-genetic-variants) — Genetic risk factors
• [MSA Treatment](/therapeutics/multiple-system-atrophy-msa-treatment) — Current therapeutic options
• [MSA Pathway](/mechanisms/multiple-system-atrophy-pathway) — Mechanistic pathway
• [Parkinson's Disease Knowledge Gaps](/gaps/parkinsons) — PD-specific gaps
• [Dementia with Lewy Bodies Knowledge Gaps](/gaps/dementia-lewy-bodies) — DLB-specific gaps
• [Alpha-Synuclein Pathway](/mechanisms/alpha-synuclein-pathology) — Shared α-synuclein mechanisms

See Also

• [Spinal Trigeminal Nucleus in Neurodegeneration](/wiki/cell-types-spinal-trigeminal-nucleus-neurodegeneration) — associated_with
• [Synucleinopathies](/wiki/mechanisms-synucleinopathies) — contributes_to
• [Gap Analysis & Research Strategy](/wiki/gaps-gap-analysis) — associated_with
• [Lateral Habenula in Depression](/wiki/cell-types-lateral-habenula-in-depression) — associated_with

Pathway Diagram

The following diagram shows the key molecular relationships involving MSA Knowledge Gaps — Alpha-Synucleinopathy Research Priorities discovered through SciDEX knowledge graph analysis: